Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Capital One Financial Corp. (COF) vs Moderna, Inc. (MRNA) Price & Performance

Capital One Financial Corp.Trade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Capital One Financial Corp. vs Moderna, Inc. — how do they compare? Capital One Financial Corp. trades at $219.75 (market cap $134.45B), while Moderna, Inc. trades at $61.74 (market cap $24.18B). The key difference: Capital One Financial Corp. is far larger — about 5.6× Moderna, Inc.'s market cap, and Capital One Financial Corp. pays a 1.46% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

COFMRNA
Market Cap
$134.45B$24.18B
Sector
FinancialsHealth
52-Week High
$257.94$81.80
52-Week Low
$176.10$22.36
Dividend Yield
1.46%
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Capital One Financial Corp.

Capital One Financial (COF) trades at $218.97, up 0.56% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $251.60. Recent Q2 2026 earnings beat expectations with EPS of $5.81, while revenue growth accelerated to $53.43B in 2025. The Discover integration is on track, targeting $2.5B in synergies by late 2027, supporting double-digit EPS growth projections.

The outlook is positive, driven by strong card growth, technology advantages, and merger synergies, but risks include integration execution, credit loss provisions, and macroeconomic sensitivity. With a P/E of 12.07 and 63% analyst buy ratings, the stock offers value if Discover benefits materialize as planned.

Moderna, Inc.

Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.

Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Capital One Financial Corp.

Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.

Read more on COF

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA